Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
PinCell srl (Italy)
Homepage:
pincell.it
Alternate names:
PinCell,
PinCell srl
ROR:
04pfgav07
OpenAlex ID:
I4405261050
Recent progress in Stevens–Johnson syndrome/toxic epidermal necrolysis: diagnostic criteria, pathogenesis and treatment
2024
·
Natsumi Hama
, Shigeki Aoki
, et al.
·
British Journal of Dermatology
·
85
PDF
Blocking soluble Fas Ligand ameliorates pemphigus: PC111 efficacy in ex-vivo human pemphigus models
2023
·
Roberta Lotti
, Jennifer E. Hundt
, et al.
·
Frontiers in Immunology
·
14
PDF
Advancements in Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis Treatment: Utilizing Fas–FasL Inhibition to Target Cell Death Signaling Pathways for Practical Human Application
2024
·
Yuki Saito
, Roberta Lotti
, et al.
·
Journal of Investigative Dermatology
·
6
PDF
Advances in Pemphigus and Pemphigoid: A Report of the International Meeting of the Pemphigus and Pemphigoid Foundation in Thessaloniki, Greece
2024
·
Meropi Karakioulaki
, Patrick Dunn
, et al.
·
JID Innovations
·
5
PDF
Selective detection of simple and doublegrounding within the medium voltage electrical networks with compensated null
2009
·
D. Toader
, P. Ruset
, et al.
·
4
Treatment of pemphigus and other neglected skin conditions with PC111, a human anti-Fas Ligand monoclonal antibody: a potential disease modifier
2025
·
Roberta Lotti
, Antonino Amato
, et al.
·
Journal of Dermatological Treatment
·
3
PDF
Soluble Fas Ligand, an overlooked target of therapy in dermatological and non-dermatological conditions
2026
·
Roberta Lotti
, Brydon Bennett
, et al.
·
Journal of Dermatological Treatment
·
2
013 Generation of a humanized Fas Ligand mouse and its application in pemphigus: a new platform for the study of PC111 antibody
2025
·
R Lotti
, A Marconi
, et al.
·
Journal of Investigative Dermatology
·
1
Placebo Response on Attention-Deficit/Hyperactivity Disorder Ratings: Application to Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder 3-Month Outcomes
2025
·
L. Eugene Arnold
, Hernan Bozzolo
, et al.
·
Journal of Child and Adolescent Psychopharmacology
·
1
125 Treatment of pemphigus and other neglected skin conditions with PC111, a human anti-Fas Ligand monoclonal antibody: a potential disease modifier
2025
·
C Pincelli
, R Lotti
, et al.
·
Journal of Investigative Dermatology
Corrigendum: Blocking soluble Fas Ligand ameliorates pemphigus: PC111 efficacy in ex-vivo human pemphigus models
2024
·
Roberta Lotti
, Jennifer E. Hundt
, et al.
·
Frontiers in Immunology
PDF
LB1750 PC111, an anti-FasL neutralizing antibody, blocks pemphigus blister formation in in-vitro, ex-vivo and in-vivo human models
2023
·
R. Lotti
, A. Marconi
, et al.
·
Journal of Investigative Dermatology
PDF
016 PC111, a novel, First In Class, human anti-FasL antibody for the treatment of Pemphigus: a translational study
2022
·
R. Lotti
, A. Marconi
, et al.
·
Journal of Investigative Dermatology
PDF
028 PC111, a monoclonal anti-Fas Ligand antibody, blocks blister formation in human pemphigus
2021
·
R. Lotti
, A. Marconi
, et al.
·
Journal of Investigative Dermatology
PDF
Show more works
View as search
Works count:
14
Citation count:
217
Year
Topic
Type